Free Trial
NASDAQ:OSRH

OSR Q1 2025 Earnings Report

OSR logo
$0.24 -0.01 (-2.83%)
As of 10/2/2026 03:59 PM Eastern

OSR EPS Results

Actual EPS
-$1.04
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

OSR Revenue Results

Actual Revenue
$0.76 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

OSR Announcement Details

Quarter
Q1 2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

OSR Earnings Headlines

Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.tc pixel
OSR Holdings Stock Price History
See More OSR Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like OSR? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OSR and other key companies, straight to your email.

About OSR

OSR (NASDAQ:OSRH) Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D "platform technologies" versus "assets only" companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.

View OSR Profile